Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02974361Phase 1Completed

Impact of Excipients on Pharmacokinetics of OXPzero(TM) Ibuprofen

Role: lead

NCT02521207Phase 1Completed

Pilot Study of OXP001(2) and Brufen in Healthy Subjects

Role: lead

NCT02408978Phase 1Completed

Pilot Study of OXP005 to Assess Gastroduodenal Irritation

Role: lead

NCT02351024Phase 1Completed

Phase I Study PK Study With OXP005 and Naprosyn

Role: lead

NCT02050958Phase 1Completed

Pilot Study of OXP001 and Brufen in Healthy Subjects

Role: lead

All 5 trials loaded